ARWR Stock Analysis: Arrowhead Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 12.381m USD | 12M Return: 318.8% | US04280A1007 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 109M
Qual. Beats: 0
Rev. Trend: 62.9%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a U.S.-based, clinical-stage biotechnology company that develops RNA interference (RNAi) therapeutics aimed at silencing disease-associated genes, primarily targeting intractable metabolic, cardiovascular, and liver-related conditions. Its pipeline is led by two Phase 3 assets - plozasiran (targeting apolipoprotein C-III) and zodasiran (targeting angiopoietin-like protein 3) - with several earlier-stage candidates in Phase 1/2a development, including programs against INHBE, ACVR1C, RAGE, MAPT, C3, and CFB. The companys business model is typical of pre-commercial RNAi developers, generating revenue primarily through collaboration and license agreements with large pharmaceutical partners, including GSK, Takeda, Amgen, and Sarepta Therapeutics. Founded in 2003, Arrowhead is headquartered in Pasadena, California, and operates within the biotechnology sub-industry of the broader health care sector.
- Plozasiran Phase 3 PALISADE readout in FCS approaches
- Takeda and GSK milestones add collaboration revenue
- Rising R&D spend strains cash runway ahead of product launches
| Net Income: -320.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA -0.96 > 1.0 |
| NWC/Revenue: 207.3% < 20% (prev 126.1%; Δ 81.21% < -1%) |
| CFO/TA -0.03 > 3% & CFO -59.1m > Net Income -320.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (143.4m) vs 12m ago 3.12% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 38.34% > 50% (prev 43.21%; Δ -4.87% > 0%) |
| Interest Coverage Ratio: -2.45 > 6 (EBIT TTM -226.4m / Interest Expense TTM 92.6m) |
| A: 0.66 (Total Current Assets 1.67b - Total Current Liabilities 283.3m) / Total Assets 2.11b |
| B: -0.91 (Retained Earnings -1.92b / Total Assets 2.11b) |
| C: -0.13 (EBIT TTM -226.4m / Avg Total Assets 1.75b) |
| D: 0.28 (Book Value of Equity 465.5m / Total Liabilities 1.65b) |
| Altman-Z'' = 0.77 = B |
| DSRI: 0.79 (Receivables 8.56m/9.70m, Revenue 669.5m/596.6m) |
| GMI: 1.00 (GM 96.22% / 96.43%) |
| AQI: 0.88 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 1.12 (Revenue 669.5m / 596.6m) |
| TATA: -0.12 (NI -320.0m - CFO -59.1m) / TA 2.11b) |
| Beneish M = -3.20 (Cap -4..+1) = AA |
As of August 25, 2026, the stock is trading at USD 86.73 with a total of 1,104,361 shares traded. Over the past week, the price has changed by -2.22%, over one month by +1.32%, over three months by +10.23% and over the past year by +318.78%.
Current recommended Stop Loss: 79.20 (which is 8.7% or 2.2 ATR below the current price).
Arrowhead Pharmaceuticals has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy ARWR.
- StrongBuy: 7
- Buy: 4
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 110.2 | 27% |
P/E Forward = 111.1111
P/S = 18.5457
P/B = 26.9232
P/EG = -1.32
Revenue TTM = 669.5m USD
EBIT TTM = -226.4m USD
EBITDA TTM = -200.6m USD
Long Term Debt = 824.1m USD (from longTermDebt, last quarter)
Short Term Debt = 40.0m USD (from shortTermDebt, last quarter)
Debt = 983.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 119.6m
Net Debt = -345.9m USD (calculated: Debt 983.7m - CCE 1.33b)
Enterprise Value = 12.0b USD (12.4b + Debt 983.7m - CCE 1.33b)
Interest Coverage Ratio = -2.45 (Ebit TTM -226.4m / Interest Expense TTM 92.6m)
EV/FCF = -62.56x (Enterprise Value 12.0b / FCF TTM -192.4m)
FCF Yield = -1.60% (FCF TTM -192.4m / Enterprise Value 12.0b)
FCF Margin = -28.74% (FCF TTM -192.4m / Revenue TTM 669.5m)
Net Margin = -47.79% (Net Income TTM -320.0m / Revenue TTM 669.5m)
Gross Margin = unknown ((Revenue TTM 669.5m - Cost of Revenue TTM 23.9m) / Revenue TTM)
Tobins Q-Ratio = 5.70 (Enterprise Value 12.0b / Total Assets 2.11b)
Interest Expense / Debt = 9.41% (Interest Expense 92.6m / Debt 983.7m)
Taxrate = 41.56% (21.4m / 51.5m)
NOPAT = -132.3m (EBIT -226.4m * (1 - 41.56%)) [loss with tax shield]
Current Ratio = 5.37 (Total Current Assets 1.67b / Total Current Liabilities 311.1m)
Debt / Equity = 2.11 (Debt 983.7m / totalStockholderEquity, last quarter 465.5m)
Debt / EBITDA = 1.72 (negative EBITDA) (Net Debt -345.9m / EBITDA -200.6m)
Debt / FCF = 1.80 (negative FCF - burning cash) (Net Debt -345.9m / FCF TTM -192.4m)
Total Stockholder Equity = 528.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -18.32% (Net Income -320.0m / Total Assets 2.11b)
RoE = -60.54% (Net Income TTM -320.0m / Total Stockholder Equity 528.5m)
RoCE = -16.74% (EBIT -226.4m / Capital Employed (Equity 528.5m + L.T.Debt 824.1m))
RoIC = -7.21% (negative operating profit) (NOPAT -132.3m / Invested Capital 1.84b)
WACC = 12.51% (E(12.4b)/V(13.4b) * Re(13.07%) + D(983.7m)/V(13.4b) * Rd(9.41%) * (1-Tc(0.42)))
Discount Rate = 13.07% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.99 | Cagr: 6.94%
[DCF] Fair Price = unknown (Cash Flow -192.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.10 | # QB: 0
Revenue Correlation: 62.87 | Revenue CAGR: 195.1% | SUE: 0.20 | # QB: 0
EPS current Quarter (2026-12-31): EPS=-1.41 | Chg30d=-4.34% | Revisions=-25% | Analysts=5
EPS current Year (2026-09-30): EPS=-3.51 | Chg30d=-16.81% | Revisions=-67% | GrowthEPS=-34954.5% | GrowthRev=-44.2%
EPS next Year (2027-09-30): EPS=-4.87 | Chg30d=-12.37% | Revisions=-67% | GrowthEPS=-38.9% | GrowthRev=-26.6%
[Analyst] Revisions Ratio: -81% (up=0, down=13)